![]() Avoid use of live vaccines in patients treated with TREMFYA ®. ![]() Prior to initiating TREMFYA ®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Do not administer TREMFYA ® to patients with active TB infection. Monitor patients for signs and symptoms of active TB during and after TREMFYA ® treatment. Initiate treatment of latent TB prior to administering TREMFYA ®. Pre-Treatment Evaluation for Tuberculosis (TB)Įvaluate patients for TB infection prior to initiating treatment with TREMFYA ®. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA ® until the infection resolves. ![]() Instruct patients receiving TREMFYA ® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. Treatment with TREMFYA ® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.Ĭonsider the risks and benefits of treatment prior to prescribing TREMFYA ® in patients with a chronic infection or a history of recurrent infection. TREMFYA ® may increase the risk of infection. If a serious hypersensitivity reaction occurs, discontinue TREMFYA ® and initiate appropriate therapy. Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA ®. TREMFYA ® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |